CA 19-9 as a prognostic index after resection for pancreatic cancer.
Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for pancreatic cancer. Patients with preoperative CA 19-9 levels < 200 U/ml had significantly better prognosis than those with CA 19-9 > 200 U/ml (P < 0.001). Serum tumor marker normalized in 14 patients after tumor resection, and survival in this group was significantly higher than that of patients with persistently elevated CA 19-9 (P < 0.0001). Prognosis was also influenced by absence of lymph node metastases (P < 0.02) and radicality of resection (P < 0.005). Elevation of serum CA 19-9 levels after operation well predicted tumor recurrence from 1-10 months before clinical and radiological evidence. CA 19-9 determination is useful as a prognostic index after resection for pancreatic carcinoma and as a surveillance test in monitoring the efficacy of treatment.
Sperti
C
C
Department of Surgery, University of Padua, Italy.
Pasquali
C
C
Catalini
S
S
Cappellazzo
F
F
Bonadimani
B
B
Behboo
R
R
Pedrazzoli
S
S
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000601:surgery*; D011379:Prognosis; D012008:Recurrence; D012044:Regression Analysis; D016019:Survival Analysis
D015295:Antigens, Tumor-Associated, Carbohydrate